A handful of biotech companies are pursuing the development of microbiome drugs, and many prominent investors are placing their bets. With $35 million series B funding led by Sequoia Capital, Whole Biome is on track to start selling a capsule for type 2 diabetes early next year. Whole Biome’s capsule helps patients restore gut bacteria, that […]

THIS ARTICLE IS EXCLUSIVE FOR KARMA MEMBERS

If you are an existing Karma member, please login using the form below.

If you are a guest, you can access this article - plus much more - with our 7-day FREE trial. Click here to register. No credit card required.